Method for in-vitro storage of ex-vivo mitochondria
By introducing mitochondria into nucleus-free and organelles-free red blood cells, red blood cells provide storage conditions close to the intracellular environment, the problem of short storage time in mitochondria in vitro is solved, and long-term protection and stable storage of mitochondrial function and activity are achieved.
Patent Information
- Application Number
- PCT/CN2024/101513
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-05
- Filing Date
- 2024-06-26
- Publication Date
- 2024-11-14
AI Technical Summary
The existing in vitro storage methods of mitochondria are inorganic salts and lack antioxidant active substances, which cannot effectively protect the activity and function of mitochondria, resulting in a short storage time, limiting mitochondria-related research and application.
Wireless chondrial cells are used as carriers, and mature erythrocytes provide storage conditions closest to the intracellular environment. By introducing mitochondria into nucleus-free and organelles-free erythrocytes, a method for protecting mitochondria function and activity is provided.
It significantly extends the in vitro storage time of mitochondria, protects the function and activity of mitochondria, avoids reprogramming of respiratory modes, and simplifies the recollecting process of mitochondria, and improves the operability of the storage system.
Smart Images

Figure CN2024101513_14112024_PF_FP_ABST
Abstract
Description
A method for storing isolated mitochondria in vitro Technical Field
[0001] The present invention relates to the field of biological technology, and in particular to an in vitro storage method for isolated mitochondria. Background Art
[0002] Mitochondria are involved in the occurrence and development of various pathophysiological processes, and research on mitochondria has attracted increasing attention. Maintaining mitochondrial activity and function in vitro is a necessary condition for conducting mitochondrial research.
[0003] Currently, the main methods for preserving isolated mitochondria in clinical and experimental settings are mitochondrial storage solution or 0.01M PBS (Phosphate-Buffered Saline). These two storage methods primarily maintain mitochondrial activity by providing an appropriate osmotic pressure and neutral pH environment. However, because these storage solutions primarily consist of inorganic salts and lack antioxidant activity, their ability to protect key mitochondrial enzymes is limited, making them inadequate for long-term in vitro storage of mitochondria and limiting mitochondrial-related research and applications.
[0004] Existing technologies can achieve the introduction of mitochondria into nucleated cells containing complete organelle units, such as white blood cells, lymphocytes, etc. This type of technology mostly introduces mitochondria into cells with intact structure but impaired function. Its essential purpose is to repair the damaged mitochondrial function of the recipient cells through mitochondrial transplantation, and ultimately repair or enhance the function of the recipient cells. The purpose is not to preserve mitochondria in vitro. In addition, mitochondria perform biosynthesis and energy supply functions in target cells, and their respiratory pattern is regulated by the target cell environment, so that the function and type of mitochondria are reprogrammed in the recipient cells, losing the original characteristics of the mitochondria. This type of mitochondrial cell transplantation and preservation cannot meet the maintenance and protection of the original characteristics of the mitochondria.
[0005] Summary of the Invention
[0006] The present invention addresses the problems of poor in vitro preservation and short storage time of mitochondria by innovatively using mitochondria-free cells as carriers to provide mitochondria with storage conditions closest to the intracellular environment to protect mitochondrial function and activity, thereby solving the above problems.
[0007] The inventors discovered that, in nucleated cells, if the recipient cell's own mitochondria are not cleared, the heterogeneous mitochondria will eventually be eliminated by the cells, making it impossible to preserve the foreign mitochondria for a long time. Furthermore, the complex cellular components and organelles in such nucleated cells increase the difficulty of re-extracting mitochondria, thereby reducing the purity of the mitochondria.
[0008] Specifically, the inventors used cells without mitochondria as carriers (preferably, mature red blood cells, which naturally lack nuclei and organelles, were selected as carriers) to provide storage conditions for mitochondria that are closest to the intracellular environment, greatly protecting mitochondrial function and activity and prolonging the in vitro storage time of mitochondria. At the same time, benefiting from the simple composition and structure of red blood cells, mitochondria, as a sensitive organelle, are not easily stimulated by intracellular components to undergo respiratory reprogramming. Moreover, the method for recollecting mitochondria in red blood cells is simple, that is, it is relatively convenient to release the mitochondria contained in the red blood cells, and does not require complicated separation steps and separation reagents, which increases the operability of this storage system.
[0009] The embodiments of the present invention are achieved through the following technical solutions:
[0010] A method for storing isolated mitochondria in vitro mainly involves storing the isolated mitochondria in a recipient cell that does not have mitochondria. Preferably, the recipient cell also does not have a nucleus, which is more conducive to the entry of exogenous cells. Specifically, the method comprises the following steps:
[0011] S1. Extracting red blood cells and mitochondria from the same or different subjects, and preparing red blood cell suspensions and mitochondrial suspensions, respectively;
[0012] S2. Introducing mitochondria into red blood cells: The mitochondrial suspension obtained in S1 is mixed with the red blood cell suspension, and the supernatant is removed by centrifugation to obtain a red blood cell pellet containing mitochondria. The cells are then dispersed in red blood cell preservation solution.
[0013] Furthermore, the following steps are included:
[0014] 1.1 Red blood cell extraction
[0015] Mice (nude, Balb / C, C57BL / 6, Kunming mice) were anesthetized by intraperitoneal injection of 1-3 mL of a 4%-10% anesthetic (phenobarbital sodium, pentobarbital sodium, thiopental sodium, ethyl carbamate, chloral hydrate). 0.1-1.5 mL of peripheral blood was collected from the mice and centrifuged at 100-2000 × g for 1-20 minutes at 4°C-25°C. After centrifugation, the supernatant was removed to obtain the red blood cell pellet, which was resuspended in 1-1000 mL of PBS for later use.
[0016] 1.2 Mitochondrial Extraction
[0017] Mice (nude, Balb / C, C57BL / 6) were killed by cervical dislocation, and then mouse tissues (heart, muscle, spleen, kidney, liver) or peripheral blood leukocytes were isolated and digested with (0.05%-0.5%) trypsin at 4℃-37℃ for 15-120 minutes. After mechanical grinding, the tissue was filtered into a single cell suspension using a 50-200 mesh cell sieve and centrifuged at 100-2000×g for 1-20 minutes at 4℃-25℃. After centrifugation, the supernatant was removed to obtain a cell pellet. The cells were treated with 1-100 times the volume of the cell pellet with mitochondrial separation solution and mitochondrial lysis solution at 4℃-25℃ for 5-120 minutes, followed by centrifugation at 100-2000g for 1-20 minutes at 4℃-25℃. After centrifugation, the supernatant was removed to obtain a mitochondrial pellet. The mitochondria were resuspended in 1-1000mL PBS for later use.
[0018] 1.3 Importing mitochondria into red blood cells
[0019] Mix the mitochondrial suspension and red blood cell suspension obtained in 1.1 and 1.2 in a ratio of 20:1-1:20, centrifuge at 100-2000g for 1-20 minutes at 4°C-25°C, remove the supernatant after centrifugation, and obtain the red blood cell pellet containing mitochondria. Then disperse the cells in 1-100 mL of red blood cell preservation solution.
[0020] The technical solutions of the embodiments of the present invention have at least the following advantages and beneficial effects:
[0021] The present invention addresses the problems of poor in vitro preservation and storage period of mitochondria, and innovatively utilizes cells that naturally lack nuclei and organelles as carriers, preferably mature red blood cells, to provide storage conditions for mitochondria that are closest to the intracellular environment, greatly protecting mitochondrial function and activity, and extending the in vitro storage time of mitochondria. At the same time, benefiting from the simple composition and structure of red blood cells, mitochondria, as a sensitive organelle, are not easily stimulated by intracellular components to undergo respiratory reprogramming. Moreover, the method for recollecting mitochondria in red blood cells is simple, which means that the mitochondria contained in the red blood cells can be released more easily without the need for complex separation steps and separation reagents, thereby increasing the operability of this storage system. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other relevant drawings can be obtained based on these drawings without paying any creative work.
[0023] FIG1 is a schematic diagram of the co-localization of red blood cells and mitochondria provided in Experimental Example 1 of the present invention (Mito Tracker: mitochondrial marker; DiO: cell membrane marker);
[0024] FIG2 is a schematic diagram of the encapsulation efficiency at different mitochondria / erythrocyte mixing ratios provided in Experimental Example 2 of the present invention;
[0025] FIG3 is a schematic diagram of the protective effect of red blood cells on mitochondrial activity provided in Experimental Example 3 of the present invention;
[0026] FIG4 is a schematic diagram of the repair ability of mitochondria to damaged myocardial cells under different storage methods provided in Experimental Example 4 of the present invention; DETAILED DESCRIPTION
[0027] To make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention are described clearly and completely below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer are used. Where the manufacturer of the reagents or instruments is not specified, all are conventional products that can be purchased commercially.
[0028] Example 1
[0029] An in vitro storage method for isolated mitochondria comprises the following steps:
[0030] C57BL / 6 mice were anesthetized by intraperitoneal injection of 1.5 mL of 4% chloral hydrate, and 0.5 mL of peripheral blood was collected from the mice and centrifuged at 800 × g for 10 minutes at 4°C. After centrifugation, the supernatant was removed to obtain the red blood cell pellet.
[0031] Mouse heart tissue was then isolated and digested with 0.25% trypsin at 37°C for 60 minutes. After mechanical grinding, the tissue was filtered into a single-cell suspension using a 70-mesh cell sieve and centrifuged at 300×g for 20 minutes at 25°C. The supernatant was removed to obtain a cell pellet, and the red blood cells were resuspended in 1 mL of PBS for later use. The cells were treated with 10 times the volume of the cell pellet and mitochondrial isolation buffer and mitochondrial lysis buffer at 4°C for 10 minutes, followed by centrifugation at 800g for 5 minutes at 25°C. The supernatant was removed to obtain a mitochondrial pellet, which was resuspended in 1 mL of PBS for later use. The mitochondrial suspension and red blood cell suspension were mixed in a 1:1 ratio and centrifuged at 800g for 20 minutes at 4°C. The supernatant was removed to obtain a red blood cell pellet containing mitochondria, and the cells were then dispersed in 1 mL of red blood cell preservation solution (PBS).
[0032] Example 2
[0033] (2) Kunming mice were anesthetized by intraperitoneal injection of 1.5 mL of 5% sodium phenobarbital. 1.5 mL of peripheral blood was collected from the mice and centrifuged at 800 g for 5 minutes at 25°C. After the centrifugation, the supernatant was removed to obtain the red blood cell pellet. The mouse heart tissue was then isolated and digested with 0.20% pancreatic enzyme at 25°C for 120 minutes. After mechanical grinding, the tissue was filtered into a single-cell suspension using a 40-mesh cell sieve and centrifuged at 800 g for 15 minutes at 25°C. The supernatant was removed after centrifugation to obtain a cell pellet, and the red blood cells were resuspended in 2 mL of PBS for later use; the cells were treated with 10 times the volume of the cell pellet and mitochondrial separation buffer at 25°C for 5 minutes, followed by centrifugation at 800 g for 20 minutes at 25°C. The supernatant was removed after centrifugation to obtain a mitochondrial pellet, and the mitochondria were resuspended in 5 mL of PBS for later use; the mitochondrial suspension and the red blood cell suspension were mixed in a ratio of 2:1, centrifuged at 800 g for 20 minutes at 25°C, and the supernatant was removed after centrifugation to obtain a red blood cell pellet containing mitochondria, and the cells were then dispersed in 2 mL of red blood cell preservation buffer PBS.
[0034] Example 3
[0035] Balb / C mice were anesthetized by intraperitoneal injection of 1 mL of 8% chloral hydrate. 1 mL of peripheral blood was collected and centrifuged at 800 g for 10 minutes at 4°C. The supernatant was removed after centrifugation to obtain the red blood cell pellet. The mouse heart tissue was then isolated and digested with 0.5% pancreatic enzyme at 37°C for 60 minutes. After mechanical grinding, the tissue was filtered into a single-cell suspension using a 70-mesh cell sieve and centrifuged at 400 g for 20 minutes at 4°C. The supernatant was removed after centrifugation to obtain a cell pellet, and the red blood cells were resuspended in 1 mL PBS for later use; the cells were treated with 10 times the volume of the cell pellet and mitochondrial separation buffer at 25°C for 4 minutes, followed by centrifugation at 600 g for 20 minutes at 25°C. The supernatant was removed after centrifugation to obtain a mitochondrial pellet, and the mitochondria were resuspended in 10 mL PBS for later use; the mitochondrial suspension and the red blood cell suspension were mixed in a ratio of 1:5, centrifuged at 800 g for 5 minutes at 20°C, and the supernatant was removed after centrifugation to obtain a red blood cell pellet containing mitochondria, and the cells were then dispersed in 5 mL of red blood cell preservation solution PBS.
[0036] Example 4
[0037] C57BL / 6 mice were anesthetized by intraperitoneal injection of 0.5 mL of 10% sodium pentobarbital. 0.5 mL of peripheral blood was collected from the mice and centrifuged at 800 g for 10 minutes at 4°C. The supernatant was removed after the centrifugation to obtain the red blood cell pellet. The mouse heart tissue was then isolated and digested with 0.25% pancreatic enzyme at 37°C for 60 minutes. After mechanical grinding, the tissue was filtered into a single-cell suspension using a 700-mesh cell sieve and centrifuged at 300 g for 20 minutes at 25°C. The supernatant was removed after centrifugation to obtain a cell pellet, and the red blood cells were resuspended in 1 mL PBS for later use; the cells were treated with 10 times the volume of the cell pellet and mitochondrial separation buffer at 4°C for 20 minutes, followed by centrifugation at 400 g for 25 minutes at 25°C. The supernatant was removed after centrifugation to obtain a mitochondrial pellet, and the mitochondria were resuspended in 10 mL PBS for later use; the mitochondrial suspension and the red blood cell suspension were mixed in a ratio of 5:1, centrifuged at 800 g for 20 minutes at 4°C, and the supernatant was removed after centrifugation to obtain a red blood cell pellet containing mitochondria. The cells were then dispersed in 1 mL of red blood cell preservation solution Saline.
[0038] Experimental Example 1 - Construction and Verification of the Mitochondrial Red Blood Cell Storage System
[0039] The red blood cell membrane was labeled with the cell membrane green fluorescent probe DiO, and the Mito Red CMX Ros was used to label mitochondria. The labeled mitochondrial suspension and red blood cell suspension were then divided into the following groups according to protein content: number of cells = 80 μg: 10 × 10 6 The mixture was mixed in a ratio of 1:1 and centrifuged at 800 g for 20 minutes at 25°C. The supernatant was removed after centrifugation to obtain a red blood cell pellet containing mitochondria, and the cells were then dispersed in 2 mL of red blood cell preservation solution. After the storage system was established, a small amount of sample was carefully added dropwise to a glass slide, and the co-localization of mitochondria and red blood cells was analyzed under a fluorescence confocal microscope. The results showed that the fluorescence of the mitochondrial marker and the fluorescence of the red blood cell membrane marker showed a high degree of co-localization, indicating that the method of the present invention can successfully introduce mitochondria into red blood cells. The experimental results are shown in Figure 1.
[0040] Experimental Example 2 - Encapsulation efficiency of mitochondrial red blood cell storage system
[0041] Using Mito Mitochondria were labeled with Red CMX Ros, and then 10 μg, 20 μg, 40 μg, 80 μg, 150 μg, or 200 μg of labeled mitochondrial suspension was mixed with 10 × 10 6The red blood cells were mixed and centrifuged at 800g for 20 minutes at 25°C. After the centrifugation, the supernatant was removed to obtain the red blood cell pellet containing mitochondria. The cells were then dispersed in 2mL of red blood cell preservation solution. After the storage system with different mixing ratios was established, the fluorescence intensity of mitochondrial markers in red blood cells was statistically analyzed by flow cytometry. The results showed that the mitochondrial suspension and red blood cell suspension were based on protein content: cell number = 200μg: 10×10 6 The highest mitochondrial encapsulation efficiency can be achieved by mixing the two components in a certain ratio. The experimental results are shown in Figure 2.
[0042] Experimental Example 3 - Protective Effect of Red Blood Cells on Mitochondrial Activity
[0043] Mitochondria were stored in erythrocytes, PBS, or a commercial mitochondrial storage solution. Mitochondrial ATP synthesis capacity and membrane potential levels were then compared after 24 hours of in vitro storage at 4°C using the different storage methods. The results showed that compared with freshly extracted mitochondria (transfer storage in the storage solution alone), mitochondrial ATP content decreased less in erythrocytes, while mitochondrial ATP content decreased significantly in mitochondria stored in mitochondrial storage solution. The degree of decrease in mitochondrial membrane potential in erythrocytes was significantly less than in the other two storage methods. In summary, erythrocyte encapsulation has a significant protective effect on mitochondrial activity. The experimental results are shown in Figure 3.
[0044] Experimental Example 4 - Repair ability of mitochondria on damaged myocardial cells under different storage methods
[0045] After establishing an isoproterenol (ISO)-induced cardiomyocyte injury model, the researchers used mitochondria stored in vitro at 4°C for 24 hours using different storage methods to transplant cardiomyocytes. The results showed that cardiomyocytes treated with mitochondria stored in red blood cells exhibited higher ATP levels and membrane potential, indicating that mitochondria stored in red blood cells retained their therapeutic potential. The experimental results are shown in Figure 4.
[0046] In summary, the present invention utilizes mitochondrial-free and nucleated red blood cells as carriers, providing mitochondria with storage conditions that are closest to the intracellular environment, greatly protecting mitochondrial function and activity, and extending the in vitro preservation time of mitochondria; at the same time, it also avoids the reprogramming of mitochondrial function and the elimination of heterogeneous mitochondria regulated by the cell nucleus, and is a stable means of preserving mitochondria in vitro.
[0047] In addition, the ability of PBS and mitochondrial storage solution to protect mitochondrial activity is very limited. The activity of mitochondria decreases significantly after 24 hours of in vitro storage. However, mitochondria are stored in red blood cells and can be preserved in vitro for 35 to 42 days at (4±2)°C, which can provide a long-term protective environment for mitochondria and extend the in vitro storage time of mitochondria.
[0048] The above are merely preferred embodiments of the present invention and are not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the present invention.
Claims
1. A method for storing isolated mitochondria in vitro, characterized in that: The isolated mitochondria are stored in recipient cells that do not have mitochondria; the recipient cells are mature red blood cells in the blood that do not have a nucleus.
2. The in vitro storage method of isolated mitochondria according to claim 1, characterized in that: The isolated mitochondria are isolated mitochondria isolated from donor cells, and the donor cells and the recipient cells are obtained from the same or different subjects.
3. The in vitro storage method of isolated mitochondria according to claim 2, characterized in that: The following steps are involved: S1. extracting red blood cells and mitochondria from the same or different subjects, and preparing red blood cell suspensions and mitochondrial suspensions, respectively; S2. Introducing mitochondria into red blood cells: The mitochondrial suspension obtained in S1 is mixed with the red blood cell suspension, and the supernatant is removed by centrifugation to obtain a red blood cell precipitate containing mitochondria, and the cells are then dispersed in a red blood cell preservation solution.
4. The in vitro storage method of isolated mitochondria according to claim 3, characterized in that: Step S1 includes S11. Red blood cell extraction: peripheral blood of the subject is collected and centrifuged for a period of time. After the centrifugation, the supernatant is removed to obtain the red blood cell precipitate, and the red blood cell suspension is obtained after resuspending.
5. The in vitro storage method of isolated mitochondria according to claim 3, characterized in that: Step S1 also includes S12. Mitochondrial extraction: taking the subject's tissue, digesting the tissue with pancreatic enzyme for a period of time, grinding and sieving the tissue to filter it into a single cell suspension; then centrifuging to obtain a cell precipitate, processing the cell precipitate, and then centrifuging to obtain a mitochondrial precipitate, and resuspending to obtain a mitochondrial suspension.
6. The in vitro storage method of isolated mitochondria according to claim 3, characterized in that: Step S1 also includes S13. Mitochondrial extraction: taking peripheral blood from a subject, and removing red blood cells using a red blood cell lysis solution; The cell pellet was centrifuged again to obtain a cell precipitate, the cell precipitate was treated, and then centrifuged to obtain a mitochondrial precipitate, which was then resuspended to obtain a mitochondrial suspension.
7. The in vitro storage method of isolated mitochondria according to claim 3, characterized in that: In S2, the mitochondrial suspension and the red blood cell suspension are mixed in a ratio of 20:1-1:20.
Citation Information
Patent Citations
Ablation solution, kit, ablation method, method for extracting mitochondria and application thereof
CN115029340A
In-vitro storage method of in-vitro mitochondria
CN116478920A
Mammalian cells enriched with functional mitochondria
US20180030413A1
Method for delivering exogenous mitochondria into cells
US20190276852A1
Mitochondrial treatment of organs for transplantation
US20210008106A1
